Primary Care Physician Use of Counterpart Assistant (CA) Technology Associated With Earlier Diagnosis And Less Frequent Hospitalization In Underserved Populations

Rhea-AI Summary

Counterpart Health (Nasdaq: CLOV) released a whitepaper (Oct 30, 2025) showing its Counterpart Assistant (CA) tech helped primary care teams in high Area Deprivation Index neighborhoods detect chronic disease earlier and reduce hospital use.

Key results: diagnosis rates were higher for diabetes (+75%), CKD (+89%), CHF (+89%) and COPD (+70%); CKD detected at average Stage 2 vs 3A; diabetes A1C averaged 6.8% vs 7.1%; inpatient hospitalizations fell -7.6% to -21.2% and 30-day readmissions fell -11.5% to -20.8% across four diseases.

Positive

• Diabetes diagnosis rates +75% in CA-attributed patients
• CKD diagnosis rates +89% in CA-attributed patients
• CHF diagnosis rates +89% in CA-attributed patients
• COPD diagnosis rates +70% in CA-attributed patients
• Earlier CKD detection at average Stage 2 vs Stage 3A
• Lower A1C in diabetes patients: 6.8% vs 7.1%
• All-cause inpatient hospitalizations reduced -7.6% to -21.2%
• 30-day readmissions reduced -11.5% to -20.8%

Negative

• Analysis is retrospective (observational), which limits causal inference

Insights

Health Services Data Analyst

Whitepaper reports earlier diagnoses and fewer hospitalizations in high‑ADI clinics using Counterpart Assistant.

Counterpart Assistant (CA) is described as an AI clinical‑decision tool that integrates into primary care workflows in resource‑constrained, high Area Deprivation Index neighborhoods to support earlier detection and longitudinal management of chronic disease. The whitepaper reports substantially higher first‑year diagnosis rates for diabetes (75%), CKD (89%), CHF (89%), and COPD (70%), plus earlier staging for CKD (mean Stage 2 versus Stage 3A) and lower average A1C for diabetes (mean 6.8% vs 7.1%). It also reports reductions in all‑cause inpatient hospitalizations (ranges from -7.6% to -21.2%) and 30‑day readmissions (-11.5% to -20.8%). These metrics together describe a shift from reactive acute care toward earlier identification and outpatient management in the studied cohort.

The observed associations depend on accurate attribution of patients to CA‑using primary care physicians and on retrospective comparisons within members who joined from other plans, as described. Causal claims require randomized or prospectively controlled designs; the whitepaper presents retrospective associations only. Results may reflect differences in coding, baseline engagement, or data completeness across plans and clinics; the report does not provide randomized controls, absolute counts, or statistical significance values in its summary. Treat the magnitude of percentage changes as descriptive until the full methods and tables are available.

Watch for the full methods and underlying data to judge robustness: sample sizes, inclusion criteria, risk‑adjustment approach, absolute event counts, and statistical significance reporting, ideally released with the whitepaper on or after Oct. 30, 2025. Also monitor subsequent independent validations or prospective studies and any published subgroup tables that show whether the reductions in hospitalizations and readmissions hold across all four conditions. Short‑term horizon: expect stakeholder attention immediately after release; medium term (12 months) requires follow‑up analyses or peer‑review for stronger evidence.

New whitepaper demonstrates how CA enables primary care teams in resource-constrained settings to prevent, detect, and manage chronic disease.

SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) and a leading AI-powered physician-enablement platform, today released a whitepaper demonstrating how Counterpart Assistant (CA) technology supports value‑based care in high Area Deprivation Index (ADI) neighborhoods.

Primary care in high ADI neighborhoods is frequently delivered by small, non‑urban practices operating with limited care‑coordination infrastructure and fragmented clinical data. The analysis in Counterpart’s latest whitepaper examines how CA’s advanced clinical technology supports early detection, disease progression tracking, and proactive interventions, capabilities not typically available to such practices.

Key highlights from the whitepaper include:

Higher Diagnosis Rates: Patients from socioeconomically disadvantaged neighborhoods (SEDN) attributed to a CA PCP who joined Clover Health from another MA plan were more likely to receive their first known diagnosis of diabetes, chronic kidney disease (CKD), chronic heart failure (CHF), or chronic obstructive pulmonary disease (COPD) in their first year after plan enrollment. Diagnosis rates were 75% higher for diabetes; 89% higher for CKD; 89% higher for CHF; and 70% higher for COPD.

Diagnosis at Earlier Stages: Patients from this population with CKD or diabetes were diagnosed at earlier clinical stages of disease. For CKD patients, initial clinical markers reflected CKD Stage 2, on average, versus Stage 3A. For diabetes patients, A1C levels were indicative of an earlier stage of disease with average A1Cs at 6.8% compared to 7.1% in the comparison group.

Less Frequent Acute Care Utilization: CA PCP attribution was associated with significantly less acute care utilization, including fewer all-cause inpatient hospitalizations (ranging from -7.6% to -21.2%) and 30-day readmissions (ranging from -11.5% to -20.8%) in members across all four studied chronic diseases.

These associations are consistent with a shift toward proactive, longitudinal care in clinics that face material operational constraints.

"Early detection opens a critical window for intervention before conditions progress and can fundamentally change disease trajectories in these communities that often have high chronic disease burden," said Dr. David Tsay, MD PhD, Chief Medical Officer at Counterpart Health and co-author of the whitepaper. "Our data shows that when primary care teams have the right tools, patients experience better outcomes, including fewer hospitalizations and a reduced need for acute interventions."

This whitepaper is Counterpart’s sixth retrospective data analysis measuring CA’s clinical impact. The case study builds on earlier analyses by showing that CA can streamline delivery and support more consistent, guideline‑aligned care in socioeconomically disadvantaged settings, core practices for managing complex chronic conditions.

"Many physicians today, particularly those treating underserved communities, lack the data and technology infrastructure needed to deliver effective, value-based care," said Conrad Wai, CEO of Counterpart Health. "CA addresses this gap, integrating AI-powered clinical insights directly into workflows so clinicians can identify high-risk patients and intervene earlier without adding administrative burden. This approach allows resource-constrained practices to deliver proactive care at scale.”

To learn more about Counterpart Health, visit: www.counterparthealth.com.

About Counterpart Health
Counterpart Health, a subsidiary of Clover Health Investments, Corp., or Clover Health, is a leading AI-powered physician enablement platform transforming care delivery. Born out of Clover Health as Clover Assistant, Counterpart Health’s flagship software platform, Counterpart Assistant, provides clinically intuitive insights that help clinicians better manage chronic conditions and deliver high-quality care. Counterpart Health extends this powerful data-driven technology platform beyond Clover Health’s Medicare Advantage plan, bringing its benefits to a wider audience to improve patient outcomes and reduce healthcare costs nationwide. Several published studies demonstrate the technology’s impact on Diabetes, Chronic Kidney Disease, and Congestive Heart Failure management, Chronic Obstructive Pulmonary Disease, and Clinical Quality.

Investor Relations:
Ryan Schmidt
investors@cloverhealth.com

Press Inquiries:
press@cloverhealth.com

FAQ

What did Counterpart Health announce on October 30, 2025 about CA and CLOV?

Counterpart published a whitepaper showing CA use in high ADI neighborhoods was associated with earlier diagnoses and reduced hospitalizations for chronic diseases.

How much did diabetes diagnosis rates change for CA-attributed patients in the CLOV whitepaper?

Diabetes diagnosis rates were reported as 75% higher for CA-attributed patients.

What hospitalization changes did the CLOV whitepaper report after CA implementation?

All-cause inpatient hospitalizations fell by 7.6% to 21.2% and 30-day readmissions fell by 11.5% to 20.8% across four chronic diseases.

How did CA affect clinical stage at diagnosis for CKD and diabetes in the CLOV study?

CKD was diagnosed at an average of Stage 2 vs Stage 3A; diabetes A1C averaged 6.8% vs 7.1% in the comparison group.

Does the CLOV whitepaper prove CA causes the improved outcomes?

No; the whitepaper is a retrospective data analysis, which shows associations but does not establish causation.

Which patient populations did the CLOV/Counterpart whitepaper focus on?

The analysis focused on patients in high Area Deprivation Index (ADI) or socioeconomically disadvantaged neighborhoods tied to small, resource-constrained primary care practices.